Current Issue

Clinical/translational cancer immunotherapy

• Original research: Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration (21 September, 2020)

  Hussein Sultan, Juan Wu, Valentyna I Fesenkova, Aaron E Fan, Diane Addis, Andres M Salazar, Esteban Celis
• Original research: Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort (18 September, 2020)

  Sonja Levy, Maureen J B Aarts, Ferry A L M Eskens, Kristien B M I Keymeulen, Lukas B Been, Dirk Grünhagen, Alexander van Akkooi, Mathilde Jalving, Margot E T Tesselaar
• Original research: Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia (16 September, 2020)

  Pinar Ataca Atilla, Mary K McKenna, Haruko Tashiro, Madhuwanti Srinivasan, Feiyan Mo, Norihiro Watanabe, Brian Wesley Simons, Alexandra McLean Stevens, Michele S Redell, Helen E Heslop, Maksim Mamonkin, Malcolm K Brenner, Erden Atilla
• Original research: Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study (8 September, 2020)

  Claire F Verschraegen, Guy Jerusalem, Edward F McClay, Nicholas Iannotti, Charles H Redfern, Jaafar Bennouna, Franklin L Chen, Karen Kelly, Janice Mehnert, John C Morris, Matthew Taylor, David Spigel, Ding Wang, Hans Juergen Grote, Dongli Zhou, Neru Munshi, Marcis Bajars, James L Gulley
• Original research: FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells (7 September, 2020)

  Lucia Campos Carrascosa, Adriaan A van Beek, Valeska de Ruiter, Michail Doukas, Jie Wei, Timothy S Fisher, Keith Ching, Wenjing Yang, Karlijn van Loon, Patrick P C Boor, Yannick S Rakké, Lisanne Noordam, Pascal Doornebosch, Dirk Grünhagen, Kees Verhoef, Wojciech G Polak, Jan N M IJzermans, Irene Ni, Yik Andy Yeung, Shahram Salek-Ardakani, Dave Sprengers, Jaap Kwekkeboom
• Original research: Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies (3 September, 2020)

  Haneen Shalabi, Vandana Sachdev, Amita Kulshreshtha, Julia W Cohen, Bonnie Yates, Doug R Rosing, Stanislav Sidenko, Cindy Delbrook, Crystal Mackall, Brandon Wiley, Daniel W Lee, Nirali N Shah
• Original research: Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study (31 August, 2020)

  Petros Fessas, Ahmed Kaseb, Yinghong Wang, Anwaar Saeed, David Szafron, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Mahvish Muzaffar, Musharraf Navaid, Uqba Khan, ChiehJu Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Francesca Benevento, Hannah Hildebrand, Tiziana Pressiani, Yehia I Abugabal, Nicola Personeni, Yi-Hsiang Huang, Lorenza Rimassa, Celina Ang, Thomas Marron, David J Pinato
• Original research: Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis (30 August, 2020)

  Xinru Chen, Zhonghan Zhang, Xue Hou, Yaxiong Zhang, Ting Zhou, Jiaqing Liu, Zhihuan Lin, Wenfeng Fang, Yunpeng Yang, Yuxiang Ma, Yan Huang, Hongyun Zhao, Li Zhang
• Original research: Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma (30 August, 2020)

  Pei-Chang Lee, Yee Chao, Ming-Huang Chen, Keng-Hsin Lan, I-Cheng Lee, Ming-Chih Hou, Yi-Hsiang Huang
• Original research: Durvalumab activity in previously treated patients who stopped durvalumab without disease progression (26 August, 2020)

  Siddharth Sheth, Chen Gao, Nancy Mueller, Natasha Angra, Ashok Gupta, Caroline Germa, Pablo Martinez, Jean-Charles Soria
• Original research: Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors (24 August, 2020)

  Aung Naing, Joseph P Eder, Sarina A Piha-Paul, Claude Gimmi, Elizabeth Hussey, Sen Zhang, Vera Hildebrand, Vinayak Hosagrahara, Christina Habermehl, Jacques Moisan, Kyriakos P Papadopoulos
• Original research: Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity (20 August, 2020)

  John C Flickinger Jr, Jagmohan Singh, Robert Carlson, Elinor Leong, Trevor R Baybutt, Joshua Barton, Ellen Caparosa, Amanda Pattison, Jeffrey A Rappaport, Jamin Roh, Tingting Zhan, Babar Bashir, Scott A Waldman, Adam E Snook
• Original research: Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity (20 August, 2020)

  Natasha D Sheybani, Alexandra R Witter, Eric A Thim, Hideo Yagita, Timothy N J Bullock, Richard J Price
• Original research: Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma (20 August, 2020)

  Celine Boutros, Nathalie Chaput-Gras, Emilie Lanoy, Alicia Larive, Christine Mateus, Emilie Routier, Roger Sun, Yun Gan Tao, Christophe Massard, Rastilav Bahleda, Dominique Schwob, Nathalie Ibrahim, Rita Maria Khoury Abboud, Caroline Caramella, Andrea Lancia, Lydie Cassard, Severine Roy, J -C Soria, Caroline Robert, Eric Deutsch
• Original research: Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service (18 August, 2020)

  Osama Abu-Shawer, Prabhsimranjot Singh, Eric Yenulevich, Amanda Brito, Jian Ni, Raja-Elie E Abdulnour, Shilpa Grover, Michael Manos, Peter Bowling, Nicole R LeBoeuf, Patrick Ott, F Stephen Hodi, Joseph Jacobson, Osama Rahma
• Original research: Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles (17 August, 2020)

  Jacob J Orme, Elizabeth Ann L Enninga, Fabrice Lucien-Matteoni, Heather Dale, Edwin Burgstaler, Susan M Harrington, Matthew K Ball, Aaron S Mansfield, Sean S Park, Mathew S Block, Svetomir N Markovic, Yiyi Yan, Haidong Dong, Roxana S Dronca, Jeffrey L Winters
• Original research: Intratumoral TIGIT⁺ CD8⁺ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer (16 August, 2020)

  Zhaopei Liu, Quan Zhou, Zewei Wang, Hongyu Zhang, Han Zeng, Qiuren Huang, Yifan Chen, Wenbin Jiang, Zhiyuan Lin, Yang Qu, Ying Xiong, Qi Bai, Yu Xia, Yiwei Wang, Li Liu, Yu Zhu, Le Xu, Bo Dai, Jianming Guo, Jiajun Wang, Yuan Chang, Weijuan Zhang
• Original research: Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects (11 August, 2020)

  Julia Delahousse, Charles Skarbek, Mélanie Desbois, Jean-Luc Perfettini, Nathalie Chaput, Angelo Paci
• Original research: CD163⁺ cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer (7 August, 2020)

  Saskia J Santegoets, Chantal L Duurland, Ekaterina J Jordanova, Vanessa J van Ham, Ilina Ehsan, Nikki M Loof, Vipin Narang, Charles A Dutertre, Florent Ginhoux, Sylvia L van Egmond, Marij J P Welters, Sjoerd H van der Burg
• Original research: Genetic associations of T cell cancer immune response-related genes with T cell phenotypes and clinical outcomes of early-stage lung cancer (6 August, 2020)

  Qinchaung Wang, Jianchun Gu, Linbo Wang, David W Chang, Yuanqing Ye, Maosheng Huang, Jack A Roth, Xifeng Wu
• Original research: Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8⁺ T cells (5 August, 2020)

  Sandeep Kumar, Sunil Kumar Singh, Navin Viswakarma, Gautam Sondarva, Rakesh Sathish Nair, Periannan Sethupathi, Matthew Dorman, Subhash C Sinha, Kent Hoskins, Gregory Thatcher, Basabi Rana, Ajay Rana
• Original research: Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up (4 August, 2020)

  Joost H van den Berg, Bianca Heemskerk, Nienke van Rooij, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Annelies Jorritsma-Smit, Marit M van Buuren, Pia Kvistborg, Hergen Spits, Remko Schotte, Henk Mallo, Matthias Karger, Joris A van der Hage, Michel W J M Wouters, Loes M Pronk, Marnix H Geukes Foppen, Christian U Blank, Jos H Beijnen, Bastiaan Nuijen, Ton N Schumacher, John B A G Haanen
• Original research: An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors (4 August, 2020)

  Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, Ben Wang, Shu Yi Shen, Ilias Ettayebi, Charles A Ishak, Philippe L Bedard, Albiruni Abdul Razak, Aaron R Hansen, Anna Spreafico, Dave Cescon, Marcus O Butler, Amit M Oza, Stephanie Lheureux, Neda Stjepanovic, Brendan Van As, Sarah Boross-Harmer, Lisa Wang, Trevor J Pugh, Pamela S Ohashi, Lillian L Siu, Daniel D De Carvalho
• Original research: Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma (30 July, 2020)

  Sara Bedrose, Kevin Charles Miller, Lina Altameemi, Mohamed S Ali, Sameh Nassar, Naveen Garg, Marilyne Daher, Keith D Eaton, Jeffrey Thomas Yorio, Davey B Daniel, Matthew Campbell, Keith C Bible, Mabel Ryder, Ashish V Chintakuntlawar, Mouhammed Amir Habra
• Original research: Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141⁺ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8⁺ T cells (30 July, 2020)

  Kelly-Anne Masterman, Oscar L Haigh, Kirsteen M Tullett, Ingrid M Leal-Rojas, Carina Walpole, Frances E Pearson, Jonathon Cebon, Christopher Schmidt, Liam O'Brien, Nikita Rosendahl, Ghazal Daraj, Irina Caminschi, Eric H Gschweng, Roger P Hollis, Donald B Kohn, Mireille H Lahoud, Kristen J Radford
• Original research: Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer (29 July, 2020)

  Kyoung-Ho Pyo, Sun Min Lim, Chae-Won Park, Ha-Ni Jo, Jae Hwan Kim, Mi-Ran Yun, Dohee Kim, Chun-Feng Xin, Wongeun Lee, Bianca Gheorghiu, Min Hee Hong, Hye Ryun Kim, Hyo Sup Shim, Mi Jang, Sung Sook Lee, Byoung Chul Cho
• Original research: Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses (23 July, 2020)

  Erika J Lampert, Ashley Cimino-Mathews, Joo Sang Lee, Jayakumar Nair, Min-Jung Lee, Akira Yuno, Daniel An, Jane B Trepel, Eytan Ruppin, Jung-Min Lee
• Original research: Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study (22 July, 2020)

  Chiun-Sheng Huang, Alice L Yu, Ling-Ming Tseng, Louis W C Chow, Ming-Feng Hou, Sara A Hurvitz, Richard B Schwab, James L Murray, Hsien-Kun Chang, Hong-Tai Chang, Shin-Cheh Chen, Sung-Bae Kim, Jung-Tung Hung, Shir-Hwa Ueng, Su-Hua Lee, Chwen-Cheng Chen, Hope S Rugo
• Original research: Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model (20 July, 2020)

  Sai Ping Lau, Nadine van Montfoort, Priscilla Kinderman, Melanie Lukkes, Larissa Klaase, Menno van Nimwegen, Mandy van Gulijk, Jasper Dumas, Dana A M Mustafa, Sanne L A Lievense, Christianne Groeneveldt, Ralph Stadhouders, Yunlei Li, Andrew Stubbs, Koen A Marijt, Heleen Vroman, Sjoerd H van der Burg, Joachim Aerts, Thorbald van Hall, Floris Dammeijer, Casper H J van Eijck
• Original research: In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases (19 July, 2020)

  Paul A Clark, Raghava N Sriramaneni, Won Jong Jin, Justin C Jagodinsky, Amber M Bates, Abigail A Jaquish, Bryce R Anderson, Trang Le, Jonathan A Lubin, Ishan Chakravarty, Ian S Arthur, Clinton M Heinze, Emily I Guy, Jasdeep Kler, Kelsey A Klar, Peter M Carlson, Kyung Mann Kim, John S Kuo, Zachary S Morris
• Original research: Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy (19 July, 2020)

  Sjoerd T T Schetters, Ernesto Rodriguez, Laura J W Kruijssen, Matheus H W Crommentuijn, Louis Boon, Jan Van den Bossche, Joke M M Den Haan, Yvette Van Kooyk
• Original research: ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19 (15 July, 2020)

  Riyue Bao, Kyle Hernandez, Lei Huang, Jason John Luke
• Original research: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (12 July, 2020)

  Robert J Motzer, Bernard Escudier, David F McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles, Frede Donskov, Elizabeth R Plimack, Philippe Barthélémy, Hans J Hammers, Saby George, Viktor Grünwald, Camillo Porta, Victoria Neiman, Alain Ravaud, Toni K Choueiri, Brian I Rini, Pamela Salman, Christian K Kollmannsberger, Scott S Tykodi, Marc-Oliver Grimm, Howard Gurney, Raya Leibowitz-Amit, Poul F Geertsen, Asim Amin, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir
• Original research: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort (7 July, 2020)

  Byoung Chul Cho, Amaury Daste, Alain Ravaud, Sébastien Salas, Nicolas Isambert, Edward McClay, Ahmad Awada, Christian Borel, Laureen S Ojalvo, Christoph Helwig, P Alexander Rolfe, James L Gulley, Nicolas Penel
• Original research: Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma (7 July, 2020)

  Jean Hoffman-Censits, Sumanta Pal, Constanze Kaiser, Beiying Ding, Joaquim Bellmunt
• Original research: Phase I study of the ¹⁷⁷Lu-DOTA⁰-Tyr³-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung (2 July, 2020)

  Chul Kim, Stephen V Liu, Deepa S Subramaniam, Tisdrey Torres, Massimo Loda, Giuseppe Esposito, Giuseppe Giaccone
• Original research: A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone (2 July, 2020)

  Julie N Graff, Tomasz M Beer, Joshi J Alumkal, Rachel E Slottke, William L Redmond, George V Thomas, Reid F Thompson, Mary A Wood, Yoshinobu Koguchi, Yiyi Chen, Emile Latour, Raymond C Bergan, Charles G Drake, Amy E Moran
• Original research: Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer (2 July, 2020)

  Marta Trüb, Franziska Uhlenbrock, Christina Claus, Petra Herzig, Martin Thelen, Vaios Karanikas, Marina Bacac, Maria Amann, Rosemarie Albrecht, Claudia Ferrara-Koller, Daniela Thommen, Sacha Rothschield, Spasenija Savic Prince, Kirsten D Mertz, Gieri Cathomas, Robert Rosenberg, Viola Heinzelmann-Schwarz, Mark Wiese, Didier Lardinois, Pablo Umana, Christian Klein, Heinz Laubli, Abhishek S Kashyap, Alfred Zippelius
• Original research: Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study (30 June, 2020)

  Tomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, Norio Okada, Takayuki Okuji, Masaaki Ito, Takeshi Onoue, Motomitsu Goto, Mariko Sugiyama, Taku Tsunekawa, Hiroshi Takagi, Daisuke Hagiwara, Yoshihiro Ito, Hidetaka Suga, Ryoichi Banno, Kenji Yokota, Tetsunari Hase, Masahiro Morise, Naozumi Hashimoto, Masahiko Ando, Yasushi Fujimoto, Hideharu Hibi, Michihiko Sone, Yuichi Ando, Masashi Akiyama, Yoshinori Hasegawa, Hiroshi Arima